메뉴 건너뛰기




Volumn 59, Issue 3-4, 2013, Pages 53-62

The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?

Author keywords

Atrial fibrillation; Bleeding; Efficacy; New anticoagulants; Safety; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; WARFARIN;

EID: 84885291067     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.07.003     Document Type: Review
Times cited : (29)

References (60)
  • 1
    • 84859603846 scopus 로고    scopus 로고
    • New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper
    • De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012, 59:1413-1425.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 1413-1425
    • De Caterina, R.1    Husted, S.2    Wallentin, L.3    Andreotti, F.4    Arnesen, H.5    Bachmann, F.6
  • 6
    • 77957932391 scopus 로고    scopus 로고
    • Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48)
    • Ruff C.T., Giugliano R.P., Antman E.M., Crugnale S.E., Bocanegra T., Mercuri M., et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
    • (2010) Am Heart J , vol.160 , pp. 635-641
    • Ruff, C.T.1    Giugliano, R.P.2    Antman, E.M.3    Crugnale, S.E.4    Bocanegra, T.5    Mercuri, M.6
  • 7
    • 84865807336 scopus 로고    scopus 로고
    • Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
    • Harenberg J., Marx S., Diener H.C., Lip G.Y., Marder V.J., Wehling M., et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012, 31:330-339.
    • (2012) Int Angiol , vol.31 , pp. 330-339
    • Harenberg, J.1    Marx, S.2    Diener, H.C.3    Lip, G.Y.4    Marder, V.J.5    Wehling, M.6
  • 8
    • 78649734571 scopus 로고    scopus 로고
    • Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate
    • Roskell N.S., Lip G.Y., Noack H., Clemens A., Plumb J.M. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010, 104:1106-1115.
    • (2010) Thromb Haemost , vol.104 , pp. 1106-1115
    • Roskell, N.S.1    Lip, G.Y.2    Noack, H.3    Clemens, A.4    Plumb, J.M.5
  • 9
    • 17644409026 scopus 로고    scopus 로고
    • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
    • Eriksson B.I., Dahl O.E., Buller H.R., Hettiarachchi R., Rosencher N., Bravo M.L., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005, 3:103-111.
    • (2005) J Thromb Haemost , vol.3 , pp. 103-111
    • Eriksson, B.I.1    Dahl, O.E.2    Buller, H.R.3    Hettiarachchi, R.4    Rosencher, N.5    Bravo, M.L.6
  • 10
    • 33645887346 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics
    • McGraw Hill, L. Brunton (Ed.) The dynamics of drug absorption, distribution, action, and elimination
    • Buxton I. Pharmacokinetics and pharmacodynamics. Goodman & Gilman's The pharmacological basis of therapeutics 2006, 1-39. McGraw Hill. 11 ed. L. Brunton (Ed.).
    • (2006) Goodman & Gilman's The pharmacological basis of therapeutics , pp. 1-39
    • Buxton, I.1
  • 11
    • 13244266944 scopus 로고    scopus 로고
    • Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
    • Eriksson B.I., Dahl O.E., Ahnfelt L., Kalebo P., Stangier J., Nehmiz G., et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004, 2:1573-1580.
    • (2004) J Thromb Haemost , vol.2 , pp. 1573-1580
    • Eriksson, B.I.1    Dahl, O.E.2    Ahnfelt, L.3    Kalebo, P.4    Stangier, J.5    Nehmiz, G.6
  • 12
    • 58149458160 scopus 로고    scopus 로고
    • Apixaban metabolism and pharmacokinetics after oral administration to humans
    • Raghavan N., Frost C.E., Yu Z., He K., Zhang H., Humphreys W.G., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
    • (2009) Drug Metab Dispos , vol.37 , pp. 74-81
    • Raghavan, N.1    Frost, C.E.2    Yu, Z.3    He, K.4    Zhang, H.5    Humphreys, W.G.6
  • 13
    • 79960272135 scopus 로고    scopus 로고
    • Edoxaban: a new oral direct Factor Xa inhibitor
    • Camm A.J., Bounameaux H. Edoxaban: a new oral direct Factor Xa inhibitor. Drugs 2011, 71:1503-1526.
    • (2011) Drugs , vol.71 , pp. 1503-1526
    • Camm, A.J.1    Bounameaux, H.2
  • 14
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers
    • Ogata K., Mendell-Harary J., Tachibana M., Masumoto H., Oguma T., Kojima M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50:743-753.
    • (2010) J Clin Pharmacol , vol.50 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3    Masumoto, H.4    Oguma, T.5    Kojima, M.6
  • 15
    • 42949123582 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery
    • Mueck W., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Fisher W.D., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008, 47:203-216.
    • (2008) Clin Pharmacokinet , vol.47 , pp. 203-216
    • Mueck, W.1    Eriksson, B.I.2    Bauer, K.A.3    Borris, L.4    Dahl, O.E.5    Fisher, W.D.6
  • 16
    • 84868523625 scopus 로고    scopus 로고
    • 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association
    • Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
    • (2012) Eur Heart J , vol.33 , pp. 2719-2747
    • Camm, A.J.1    Lip, G.Y.2    De Caterina, R.3    Savelieva, I.4    Atar, D.5    Hohnloser, S.H.6
  • 17
    • 84856158305 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
    • Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
    • (2011) Eur Heart J , vol.32 , pp. 2999-3054
    • Hamm, C.W.1    Bassand, J.P.2    Agewall, S.3    Bax, J.4    Boersma, E.5    Bueno, H.6
  • 18
    • 84856802635 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e419S-e494S.
    • (2012) Chest , vol.141
    • Kearon, C.1    Akl, E.A.2    Comerota, A.J.3    Prandoni, P.4    Bounameaux, H.5    Goldhaber, S.Z.6
  • 19
    • 84856797169 scopus 로고    scopus 로고
    • Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e278S-e325S.
    • (2012) Chest , vol.141
    • Falck-Ytter, Y.1    Francis, C.W.2    Johanson, N.A.3    Curley, C.4    Dahl, O.E.5    Schulman, S.6
  • 20
    • 35348879239 scopus 로고    scopus 로고
    • Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
    • Ezekowitz M.D., Reilly P.A., Nehmiz G., Simmers T.A., Nagarakanti R., Parcham-Azad K., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007, 100:1419-1426.
    • (2007) Am J Cardiol , vol.100 , pp. 1419-1426
    • Ezekowitz, M.D.1    Reilly, P.A.2    Nehmiz, G.3    Simmers, T.A.4    Nagarakanti, R.5    Parcham-Azad, K.6
  • 21
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
    • Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
    • (2007) J Thromb Haemost , vol.5 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3    Kurth, A.A.4    van Dijk, C.N.5    Frostick, S.P.6
  • 22
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    • Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
    • (2007) Lancet , vol.370 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3    Kurth, A.A.4    van Dijk, C.N.5    Frostick, S.P.6
  • 24
    • 80052232522 scopus 로고    scopus 로고
    • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
    • Oldgren J., Budaj A., Granger C.B., Khder Y., Roberts J., Siegbahn A., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32:2781-2789.
    • (2011) Eur Heart J , vol.32 , pp. 2781-2789
    • Oldgren, J.1    Budaj, A.2    Granger, C.B.3    Khder, Y.4    Roberts, J.5    Siegbahn, A.6
  • 25
    • 33644867218 scopus 로고    scopus 로고
    • Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    • Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-128.
    • (2006) J Thromb Haemost , vol.4 , pp. 121-128
    • Eriksson, B.I.1    Borris, L.2    Dahl, O.E.3    Haas, S.4    Huisman, M.V.5    Kakkar, A.K.6
  • 26
    • 33751559902 scopus 로고    scopus 로고
    • A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    • Eriksson B.I., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006, 114:2374-2381.
    • (2006) Circulation , vol.114 , pp. 2374-2381
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3    Haas, S.4    Huisman, M.V.5    Kakkar, A.K.6
  • 27
    • 28444474155 scopus 로고    scopus 로고
    • BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    • Turpie A.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., Kalebo P., et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005, 3:2479-2486.
    • (2005) J Thromb Haemost , vol.3 , pp. 2479-2486
    • Turpie, A.G.1    Fisher, W.D.2    Bauer, K.A.3    Kwong, L.M.4    Irwin, M.W.5    Kalebo, P.6
  • 29
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    • Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3    Eriksson, B.I.4    Mouret, P.5    Muntz, J.6
  • 30
  • 31
    • 65549169515 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
    • Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
    • (2009) Lancet , vol.373 , pp. 1673-1680
    • Turpie, A.G.1    Lassen, M.R.2    Davidson, B.L.3    Bauer, K.A.4    Gent, M.5    Kwong, L.M.6
  • 32
    • 79952496003 scopus 로고    scopus 로고
    • Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies
    • Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz S.D., Misselwitz F., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011, 105:444-453.
    • (2011) Thromb Haemost , vol.105 , pp. 444-453
    • Turpie, A.G.1    Lassen, M.R.2    Eriksson, B.I.3    Gent, M.4    Berkowitz, S.D.5    Misselwitz, F.6
  • 33
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
    • Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3    Zuehlsdorf, M.4    Wensing, G.5
  • 34
    • 34447317298 scopus 로고    scopus 로고
    • Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
    • Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007, 116:180-187.
    • (2007) Circulation , vol.116 , pp. 180-187
    • Agnelli, G.1    Gallus, A.2    Goldhaber, S.Z.3    Haas, S.4    Huisman, M.V.5    Hull, R.D.6
  • 35
    • 53849123533 scopus 로고    scopus 로고
    • A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study
    • Buller H.R., Lensing A.W., Prins M.H., Agnelli G., Cohen A., Gallus A.S., et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008, 112:2242-2247.
    • (2008) Blood , vol.112 , pp. 2242-2247
    • Buller, H.R.1    Lensing, A.W.2    Prins, M.H.3    Agnelli, G.4    Cohen, A.5    Gallus, A.S.6
  • 36
    • 80052485992 scopus 로고    scopus 로고
    • Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention
    • Mueck W., Lensing A.W., Agnelli G., Decousus H., Prandoni P., Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 675-686
    • Mueck, W.1    Lensing, A.W.2    Agnelli, G.3    Decousus, H.4    Prandoni, P.5    Misselwitz, F.6
  • 39
    • 84861229431 scopus 로고    scopus 로고
    • New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation
    • Tripodi A., Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med 2012, 271:554-565.
    • (2012) J Intern Med , vol.271 , pp. 554-565
    • Tripodi, A.1    Palareti, G.2
  • 40
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    • Mega J.L., Braunwald E., Mohanavelu S., Burton P., Poulter R., Misselwitz F., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3    Burton, P.4    Poulter, R.5    Misselwitz, F.6
  • 42
    • 36348978071 scopus 로고    scopus 로고
    • The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
    • Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., Deitchman D. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-2375.
    • (2007) J Thromb Haemost , vol.5 , pp. 2368-2375
    • Lassen, M.R.1    Davidson, B.L.2    Gallus, A.3    Pineo, G.4    Ansell, J.5    Deitchman, D.6
  • 43
    • 77649249878 scopus 로고    scopus 로고
    • Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    • Lopes R.D., Alexander J.H., Al-Khatib S.M., Ansell J., Diaz R., Easton J.D., et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010, 159:331-339.
    • (2010) Am Heart J , vol.159 , pp. 331-339
    • Lopes, R.D.1    Alexander, J.H.2    Al-Khatib, S.M.3    Ansell, J.4    Diaz, R.5    Easton, J.D.6
  • 45
    • 77649113258 scopus 로고    scopus 로고
    • Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    • Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
    • (2010) Lancet , vol.375 , pp. 807-815
    • Lassen, M.R.1    Raskob, G.E.2    Gallus, A.3    Pineo, G.4    Chen, D.5    Hornick, P.6
  • 46
    • 67649563209 scopus 로고    scopus 로고
    • Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial
    • Alexander J.H., Becker R.C., Bhatt D.L., Cools F., Crea F., Dellborg M., et al. Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
    • (2009) Circulation , vol.119 , pp. 2877-2885
    • Alexander, J.H.1    Becker, R.C.2    Bhatt, D.L.3    Cools, F.4    Crea, F.5    Dellborg, M.6
  • 48
    • 0034871011 scopus 로고    scopus 로고
    • A systematic review of the associations between dose regimens and medication compliance
    • Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
    • (2001) Clin Ther , vol.23 , pp. 1296-1310
    • Claxton, A.J.1    Cramer, J.2    Pierce, C.3
  • 49
    • 84866480694 scopus 로고    scopus 로고
    • Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients
    • Laliberte F., Nelson W.W., Lefebvre P., Schein J.R., Rondeau-Leclaire J., Duh M.S. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012, 29:675-690.
    • (2012) Adv Ther , vol.29 , pp. 675-690
    • Laliberte, F.1    Nelson, W.W.2    Lefebvre, P.3    Schein, J.R.4    Rondeau-Leclaire, J.5    Duh, M.S.6
  • 51
    • 77954361232 scopus 로고    scopus 로고
    • Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
    • Weitz J.I., Connolly S.J., Patel I., Salazar D., Rohatagi S., Mendell J., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641.
    • (2010) Thromb Haemost , vol.104 , pp. 633-641
    • Weitz, J.I.1    Connolly, S.J.2    Patel, I.3    Salazar, D.4    Rohatagi, S.5    Mendell, J.6
  • 52
    • 78149236861 scopus 로고    scopus 로고
    • A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
    • Fuji T., Fujita S., Tachibana S., Kawai Y. A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010, 8:2458-2468.
    • (2010) J Thromb Haemost , vol.8 , pp. 2458-2468
    • Fuji, T.1    Fujita, S.2    Tachibana, S.3    Kawai, Y.4
  • 54
    • 84880397241 scopus 로고    scopus 로고
    • Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials
    • Raskob G., Buller H., Prins M., Segers A., Shi M., Schwocho L., et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. J Thromb Haemost 2013, 11:1287-1294.
    • (2013) J Thromb Haemost , vol.11 , pp. 1287-1294
    • Raskob, G.1    Buller, H.2    Prins, M.3    Segers, A.4    Shi, M.5    Schwocho, L.6
  • 55
    • 34447639584 scopus 로고    scopus 로고
    • A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery
    • Eriksson B.I., Turpie A.G., Lassen M.R., Prins M.H., Agnelli G., Kalebo P., et al. A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007, 5:1660-1665.
    • (2007) J Thromb Haemost , vol.5 , pp. 1660-1665
    • Eriksson, B.I.1    Turpie, A.G.2    Lassen, M.R.3    Prins, M.H.4    Agnelli, G.5    Kalebo, P.6
  • 56
    • 77649141852 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)
    • Eriksson B.I., Turpie A.G., Lassen M.R., Prins M.H., Agnelli G., Kalebo P., et al. Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010, 8:714-721.
    • (2010) J Thromb Haemost , vol.8 , pp. 714-721
    • Eriksson, B.I.1    Turpie, A.G.2    Lassen, M.R.3    Prins, M.H.4    Agnelli, G.5    Kalebo, P.6
  • 57
    • 80054742836 scopus 로고    scopus 로고
    • Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2)
    • [abstract]
    • Lip G., Halperin J., Petersen P., Rodgers G., Renfurm R. Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). J Thromb Haemost 2011, 9(Suppl. 2):748. [abstract].
    • (2011) J Thromb Haemost , vol.9 , Issue.SUPPL. 2 , pp. 748
    • Lip, G.1    Halperin, J.2    Petersen, P.3    Rodgers, G.4    Renfurm, R.5
  • 58
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
    • Steg P.G., Mehta S.R., Jukema J.W., Lip G.Y., Gibson C.M., Kovar F., et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011, 32:2541-2554.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukema, J.W.3    Lip, G.Y.4    Gibson, C.M.5    Kovar, F.6
  • 59
    • 77955926663 scopus 로고    scopus 로고
    • Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
    • Leil T.A., Feng Y., Zhang L., Paccaly A., Mohan P., Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010, 88:375-382.
    • (2010) Clin Pharmacol Ther , vol.88 , pp. 375-382
    • Leil, T.A.1    Feng, Y.2    Zhang, L.3    Paccaly, A.4    Mohan, P.5    Pfister, M.6
  • 60
    • 84860526602 scopus 로고    scopus 로고
    • Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
    • Salazar D.E., Mendell J., Kastrissios H., Green M., Carrothers T.J., Song S., et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012, 107:925-936.
    • (2012) Thromb Haemost , vol.107 , pp. 925-936
    • Salazar, D.E.1    Mendell, J.2    Kastrissios, H.3    Green, M.4    Carrothers, T.J.5    Song, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.